Carbiotix evaluation of new production enzyme yields positive results
Carbiotix (publ) ("Carbiotix" or “the Company”) today announces that it has completed a comprehensive evaluation of a new production enzyme supplied by a potential strategic partner yielding positive results. The Company will now proceed with the GRAS Self Affirmation process.
Carbiotix communicated at the end of Q1 2021 that it would undertake a comprehensive evaluation of a new production enzyme supplied by a leading global enzyme producer and potential strategic partner in Q2 2021. This enzyme had the potential to accelerate achieving FDA GRAS No Objection and EFSA Novel Foods status in the US and EU respectively for AXOS food ingredients.
Kristofer Cook, CEO for Carbiotix, comments
“I am very pleased to announce that we have completed a comprehensive evaluation of this new production enzyme yielding positive results. We confirmed that the enzyme in question is effective in producing AXOS from corn bran in line with our product ambitions and intellectual property. We will now proceed with the previously communicated GRAS Self Affirmation process for AXOS.
To maintain a high level of productivity during this evaluation period, we used this time to also build up our in-house lab and competencies to explore new enzymes and prebiotic products, as well as established relationships with external partners who will be able to help accelerate development and scale-up activities. Thus, at the end of Q2, we are in a much stronger position to discover and launch new prebiotic products going forward, collaborate with key partners, and reduce our reliance on any one partner.
Overall, I am very pleased with these developments. We have not only established the preconditions for a long-term business relationship with a leading global enzyme supplier and potential strategic partner in the microbiome area but also placed Carbiotix in a much stronger position to build out a portfolio of prebiotic products beyond AXOS and have better control of its supply chain and competitive position.”
This is information that Carbiotix AB is obliged to make public according to the EU Market Abuse Regulation (MAR). The information was made publicly available by the Company’s contact person set out below on 1 July 2021.
This communication contains forward-looking statements, consisting of subjective assumptions and forecasts for future scenarios. Predictions for the future only apply as of the date they are made and are, by their nature, as is research and development work in the biotechnology segment, associated with risk and uncertainty. With this in mind, the actual outcome may deviate significantly from the scenarios as described in this press release.
For further information:
Kristofer Cook, CEO
Tel: +46 (0)708-796580
Carbiotix AB (CRBX) (www.carbiotix.com) is an award-winning biotechnology company pioneering microbiome healthcare through a range of cost-effective gut health testing services and a portfolio of microbiome modulators covering prebiotic ingredients, medical foods and therapeutics.